EPISODE · Aug 14, 2025 · 30 MIN
Current Landscape and Access Barriers for GLP-1s in Obesity
from Ipsos in the UK Podcast · host Ipsos in the UK
What happens when breakthrough drugs collide with outdated systems of access?In this episode, Ipsos' Kiran Khepar and Neil Grubert, Global Market Access Consultant, explore the friction between innovation and access, and what it means for the future of healthcare systems.GLP-1 therapies are redefining what’s possible in obesity treatment, but reimbursement pathways haven’t caught up. From out-of-pocket models to public payer resistance, we’re unpacking how market dynamics are shaping who really gets treated and who’s left behind.
What this episode covers
What happens when breakthrough drugs collide with outdated systems of access?In this episode, Ipsos' Kiran Khepar and Neil Grubert, Global Market Access Consultant, explore the friction between innovation and access, and what it means for the future of healthcare systems.GLP-1 therapies are redefining what’s possible in obesity treatment, but reimbursement pathways haven’t caught up. From out-of-pocket models to public payer resistance, we’re unpacking how market dynamics are shaping who really gets treated and who’s left behind.
NOW PLAYING
Current Landscape and Access Barriers for GLP-1s in Obesity
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m